Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia

S Cedirian; F Bruni; F Quadrelli; G Caro; M Fortuna; A Rossi; B M Piraccini; M Starace

doi:10.1111/jocd.15873

Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia

J Cosmet Dermatol. 2023 Dec;22(12):3347-3351. doi: 10.1111/jocd.15873. Epub 2023 Jul 6.

Authors

S Cedirian^{1

2}, F Bruni^{1

2}, F Quadrelli^{1

2}, G Caro³, M Fortuna³, A Rossi³, B M Piraccini^{1

2}, M Starace^{1

2}

Affiliations

¹ Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
² Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
³ Dermatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.

PMID: 37415302
DOI: 10.1111/jocd.15873

Abstract

Hair loss may change the quality of life since modern society considers hair an essential element in beauty definition. The most common causes of hair loss are androgenetic alopecia (AGA) and telogen effluvium (TE). AGA requires a lifetime use of minoxidil or finasteride (and sometimes they lose efficacy over the years), whereas TE has no standardized therapy available. Our study focuses on a novel topical regenerative preparation that, by mimicking autologous PRP, can safely and efficiently improve hair loss in patients affected by TE and AGA.

Keywords: PRP; androgenetic alopecia; growth factors; hair loss; telogen effluvium.

MeSH terms

Alopecia / drug therapy
Alopecia Areata* / drug therapy
Hair
Humans
Minoxidil / adverse effects
Quality of Life*

Substances

Minoxidil

Supplementary concepts

Diffuse alopecia